Kangbei: Subsidiary Hangzhou Kangbei's amecholic acid tablets have obtained a drug registration certificate.

Kanghongbei announced that its wholly-owned subsidiary Hangzhou Kanghongbei has received the Drug Registration Certificate issued by the National Medical Products Administration for 0.25g tranexamic acid tablets. This drug is mainly used for various bleeding caused by acute or chronic, local or systemic primary fibrinolysis hyperactivity, and secondary high-fibrinolytic state caused by diffuse intravascular coagulation. Hangzhou Kanghongbei submitted the registration application in April 2024 and recently obtained the certificate. As of now, Hangzhou Kanghongbei has invested approximately 6.27 million yuan in research and development expenses. According to national policies, this drug is considered to have passed generic drug consistency evaluation, and is expected to have a positive impact on the company's performance.